Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0.00 | $19.1M | $77.1M | $186M | $337M | $521M |
| Revenue growth | — | — | — | — | 302.7% | 141.8% | 80.8% | 54.7% |
| Operating income | — | -$54.7M | -$104M | -$173M | -$131M | -$109M | -$87.6M | -$22.1M |
| Operating margin | — | — | — | -906.1% | -170.3% | -58.6% | -26.0% | -4.2% |
| Net income | — | -$52.6M | -$103M | -$84.0M | -$136M | -$163M | -$87.9M | -$23.4M |
| Net margin | — | — | — | -438.9% | -176.0% | -87.7% | -26.1% | -4.5% |
| EPS (diluted) | — | -$4.58 | -$4.09 | -$2.77 | -$4.02 | -$4.00 | -$1.85 | -$0.47 |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | — | -$39.4M | -$89.1M | -$133M | -$120M | -$70.9M | $10.3M | $55.8M |
| Capital expenditures | — | $281K | $225K | $24.0K | $278K | $109K | $993K | $954K |
| Free cash flow | — | -$39.6M | -$89.3M | -$133M | -$120M | -$71.1M | $9.33M | $54.9M |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $52.0M | $12.0M | $142M | $31.3M | $28.0M | $286M | $223M | $297M |
| Total assets | $52.0M | $147M | $241M | $295M | $353M | $647M | $671M | $843M |
| Total liabilities | $2.45M | $16.4M | $68.8M | $174M | $211M | $398M | $445M | $528M |
| Shareholders' equity | -$17.3M | $130M | $172M | $120M | $142M | $249M | $226M | $315M |
| Retained earnings | -$17.3M | -$69.9M | -$173M | -$257M | -$393M | -$556M | -$644M | -$668M |
| Shares (wtd avg diluted) | 637K | 22.6M | 29.8M | 30.3M | 34.0M | 40.9M | 47.5M | 50.2M |
Every figure is extracted from Mirum Pharmaceuticals, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.